Two Milestones: (1) Gluetacs Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial to Evaluate GT919; (2) Gluetacs Therapeutics Announces IND Approval of GT929 from China CDE 

ON：2023-07-24 TAG：GLUETACS THERAPEUTICS

PRESS RELEASE

Shanghai, China – 24 July 2023

Two Milestones: (1) Gluetacs Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial to Evaluate GT919; (2) Gluetacs Therapeutics Announces IND Approval of GT929 from China CDE 

Milestone 1：

Gluetacs Therapeutics announced today that the first patient has been dosed in the first-in-human phase 1 trial to evaluate GT919, a glue degrader pipeline of the company, in relapsed or refractory multiple myeloma. The primary purpose of the clinical study is to access the safety, tolerability, pharmacokinetics and efficacy of GT919 in Chinese subjects.

Milestone 2：

Gluetacs Therapeutics announced today the Center for Drug Evaluation (CDE) of China has approved the Investigational New Drug (IND) application of GT929 to treat liquid tumors.

With these two milestones, Gluetacs Therapeutics has officially become a clinical-stage innovative biotech company in the field of small molecule target protein degradation. We are eager to promote the clinical trial of GT919 and GT929 to deliver new treatment to patients with clinically unmet needs under the joint efforts of research institutions, supervision departments and clinical experts to benefit the patients with liquid tumors.